Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C

Transplantation

Volumn 78, Issue 6, 2004, Pages 853-857

  Fontaine, Helene ^a   Vallet Pichard, Anais ^a   Equi Andrade, Claudia ^a   Nalpas, Bertrand ^a   Verkarre, Virginia ^a   Chaix, Marie Laure ^a   Lebray, Pascal ^a   Sobesky, Rodalphe ^a   Serpaggi, Jean ^a   Kreis, Henri ^a   Pol, Stanislas ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Chronic hepatitis C; Kidney recipients; Liver fibrosis; Necro inflammatory activity; Ribavirin

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; PREDNISOLONE; RIBAVIRIN; STEROID;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; RECIPIENT; VIRUS LOAD;

ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 4644276635     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000128911.87538.AA     Document Type: Article

References (30)

1. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-670.
2. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 291-293.
3. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-476.
4. Younossi ZM, Braun WE, Protiva DA, et al. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999; 67: 272-275.
5. Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63: 1634-1639.
6. Hestin D, Guillemin F, Castin N, et al. Pretransplant hepatitis C virus infection: A predictor of proteinuria after renal transplantation. Transplantation 1998; 65: 741-744.
7. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121-S127.
8. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-1023.
9. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 1614-1617.
10. Chan TM, Wu PC, Lau JY, et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 1414-1419.
11. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-1509.
12. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-1418.
13. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: Management of hepatitis C-2002. Hepatology 2002; 36: S1-S2.
14. Thervet E, Pol S, Legendre C, et al. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients: A pilot study. Transplantation 1994; 58: 625-628.
15. Rostaing L, Izopet J, Baron E, et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431.
16. Hanafusa T, Ichikawa Y, Yazawa K, et al. Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplant Proc 1998; 30: 122-124.
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
18. Gane EJ, Tibbs CJ, Ramage JK, et al. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8: 61-64.
19. Cattral MS, Hemming AW, Wanless IR, et al. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 1999; 67: 1277-1280.
20. Quadri R, Giostra E, Roskams T, et al. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 2002; 73: 373-378.
21. Garnier JJ, Chevallier P, Dubernard JM, et al. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transpl Proc 1997; 29: 783-786.
22. Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192.
23. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-3493.
24. Adinolfi LE, Andreana A, Utili R, et al. HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Am J Gastroenterol 1998; 93: 2162-2166.
25. Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients. J Hepatol 1998; 29: 12-19.
26. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001; 34: 1193-1199.
27. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32: 904-909.
28. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-739.
29. Pham HP, Feray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54: 1311-1319.
30. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: A case control study. Nephrol Dial Transplant 2002; 17: 129-133.